Illumina, Inc. (NASDAQ:ILMN) Receives $138.38 Average PT from Brokerages

Illumina, Inc. (NASDAQ:ILMN) has been given a consensus rating of “Hold” by the eighteen analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $138.3750.

A number of analysts have recently issued reports on the stock. Barclays boosted their target price on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research note on Friday, May 1st. Canaccord Genuity Group lowered their price objective on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a research note on Friday, May 1st. Royal Bank Of Canada initiated coverage on shares of Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on shares of Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Friday, May 1st.

Insider Buying and Selling at Illumina

In related news, Director Keith A. Meister sold 235,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the sale, the director directly owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. This represents a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Scott D. Ericksen sold 500 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $80,000.00. Following the completion of the sale, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at approximately $2,311,360. This trade represents a 3.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,002,371 shares of company stock valued at $155,472,900 in the last ninety days. 2.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Illumina

A number of large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its holdings in shares of Illumina by 17.5% during the third quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after acquiring an additional 124,246 shares in the last quarter. Elo Mutual Pension Insurance Co acquired a new position in shares of Illumina during the third quarter valued at about $2,319,000. Caprock Group LLC acquired a new position in shares of Illumina during the third quarter valued at about $1,479,000. Capital World Investors increased its holdings in shares of Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after acquiring an additional 3,331,542 shares in the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of Illumina by 2,792.2% during the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after acquiring an additional 911,843 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Down 2.6%

Shares of ILMN opened at $158.04 on Thursday. The firm has a market capitalization of $23.91 billion, a P/E ratio of 28.73, a P/E/G ratio of 3.04 and a beta of 1.50. Illumina has a 12-month low of $82.60 and a 12-month high of $177.22. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The firm has a fifty day moving average price of $138.43 and a 200-day moving average price of $133.92.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts expect that Illumina will post 5.2 earnings per share for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.